Ardea Biosciences, Inc. (Nasdaq: RDEA) reports additional positive clinical and preclinical results from its development program of lesinurad.

Lesinurad ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE